Indian pharma company Zydus Lifesciences Limited, previously known as Cadila Healthcare Limited has launched Lenalidomide Capsules, a generic of Revlimid, in the US market.

The launch of Lenalidomide Capsules follows the final approvals for 5 mg, 10 mg, 15 mg and 25 mg strengths and tentative approvals for 2.5 mg and 20 mg strength from the US Food and Drug Administration (FDA).

Lenalidomide has the approval to treat different types of cancers. The drug acts by slowing down or restricting the growth of cancer cells.

The drug is also used for treating anemia in patients with specific blood or bone marrow disorders like myelodysplastic syndromes-MDS.

The drug is being produced at Zydus Lifesciences’ formulation manufacturing facility at Ahmedabad SEZ, India.

Lenalidomide had yearly sales of $2.86 billion in the United States, as per IQVIA MAT July 2022.

  Ahmedabad, anemia, Bone Marrow Disorders, Cadila Healthcare, lenalidomide, Myelodysplastic syndrome, myelodysplastic syndromes, US, US Food and Drug Administration, USA, USFDA, Zydus Cadila, Zydus Lifesciences